Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT05849766
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 150 participants
- Registry
-
NCT05849766
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT05849766. Randomized; no masking; primary purpose treatment. Start 2023-04-27 (actual); primary completion 2024-05-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
- Condition
- Dilated Cardiomyopathy
- Intervention (Drug)
- Dapagliflozin Farxiga®
- Intervention (Drug)
- Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®
- Lead sponsor
- October 6 University
- Collaborator
- National Heart Institute, Egypt
- Collaborator
- University of Florida
Record details
- Record id
cardio:ct-nct05849766- Content hash
09e183e1728061222600023ca60bd6fac38b0c41e032f441becd423fcfa7d231